Topic: targeted cancer drugs
Immunitas Therapeutics is launching with $39 million in series A financing to propel at least one monoclonal antibody into the clinic.
Several cancer drug candidates are designed to kill tumor cells by attacking certain targets, but they work in other ways, researchers found.
Notable Labs is adding $40 million to its reserves as it scales up its capabilities with plans to take its platform worldwide.
A Boston University-led team found a novel activator of NRAS and developed a small molecule to inhibit the growth of NRAS-mutant melanoma.
South Korea’s Yuhan has licensed its lung cancer drug lazertinib to Janssen Biotech for $50 million upfront and another $1.2 billion in milestones.
Loxo is preparing for a November verdict from the FDA on larotrectinib as a treatment for solid tumors with NTRK fusions.
Phase 3 results with Daiichi Sankyo's new FLT3 inhibitor quizartinib put it on course for regulatory filings in acute myeloid leukemia.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets.
The FDA is working on a medical innovation development plan to lower healthcare costs by streamlining the path to market for targeted therapies.